

Aus der Klinik für Dermatologie und Allergologie  
der Medizinischen Fakultät der Charité – Universitätsmedizin Berlin

DISSERTATION

The mechanism of sensitivity and resistance of  
melanoma cells to tumor necrosis factor-related  
apoptosis-inducing ligand (TRAIL)

zur Erlangung des akademischen Grades  
Doctor medicinae (Dr. med.)

vorgelegt der Medizinischen Fakultät der Charité – Universitätsmedizin  
Berlin

von

Bahtier Kurbanov

aus Duschanbe. Tadschikistan

Gutachter: 1. PD Dr. rer.nat. Jürgen Eberle  
2. Prof. Dr. med. Martin Leverkus  
3. Prof. Dr. rer.nat. Christoph Hanski

Datum der Promotion: 21. November 2006  
Datum der Urkundenverleihung: 15. Dezember 2006

# CONTENT

<b>1. INTRODUCTION</b>	3
<b>1.1. Malignant Melanoma</b>	3
<b>1.1.1. Epidemiology</b>	3
<b>1.1.2. Melanoma progression</b>	4
<b>1.1.3. Clinical characteristic of early melanoma and classification</b>	4
<b>1.1.4. Prognostic parameters</b>	6
<b>1.1.5. Treatment of malignant melanoma</b>	7
<b>1.2. Apoptosis</b>	9
<b>1.2.1. Definition</b>	9
<b>1.2.2. Caspases as basal elements for proapoptotic pathways</b>	10
<b>1.2.3. Caspase inhibitors</b>	11
<b>1.3. Intrinsic (mitochondria) apoptotic pathways</b>	12
<b>1.3.1. The role of p53</b>	12
<b>1.4. Extrinsic apoptotic pathways</b>	13
<b>1.5. TRAIL and its receptors</b>	15
<b>1.5.1. TRAIL activates several pathways</b>	17
<b>1.5.2. Targeting tumors by TRAIL and its possible clinical application</b>	18
<b>1.5.3. Resistance to TRAIL</b>	23
<b>1.6. Nuclear Factor – kappa B (NF-<math>\kappa</math>B)</b>	22
<b>1.7. Melanoma and TRAIL</b>	24
<b>1.8. Objective of the study</b>	26

<b>2. MATERIALS AND METHODS</b>	28
<b>2.1. Materials</b>	28
2.1.1. Cell cultures	28
2.1.2. Cell culture media and solutions	29
2.1.3. Bacterial growth media and supplements	29
2.1.4. Antibiotics	29
2.1.5. Apoptosis stimulation agents	30
2.1.6. Enzymes	30
2.1.7. Expression plasmids	30
2.1.8. Kits	31
2.1.9. Molecular length markers	31
2.1.10. Extraction buffers for cellular proteins	31
2.1.11. Antibodies	32
2.1.12. Solutions	33
2.1.13. Chemical and radioactive substances	34
2.1.14. Equipment	35
<b>2.2. Methods</b>	36
2.2.1. Cultivation of cells	36
2.2.2. Freezing and thawing of cells	36
2.2.3. Detection of apoptosis	36
2.2.4. Cytotoxicity assay	38
2.2.5. Protein analysis	39
2.2.6. SDS-polyacrylamide gel electrophoresis	40
2.2.7. Western blotting	43
2.2.7. Immunodetection of blotted proteins	45

<b>2.2.9. Proteasome inhibition and in vitro Viability Assay</b>	46
<b>2.2.10. Fluorescence-activated cell sorting (FACS) analyses</b>	47
<b>2.2.11. Determination of NF-<math>\kappa</math>B activity</b>	49
<b>2.2.11.1. Determination of NF-<math>\kappa</math>B activation by ELISA</b>	49
<b>2.2.11.2. Electromobility shift assay</b>	52
<b>2.2.12. Restriction analysis</b>	54
<b>2.2.13. Transient transfection</b>	56
<b>2.2.14. Immunohistochemistry and Immunocytochemistry</b>	56
<b>2.2.15. Statistics and general statements</b>	57
<b>3. RESULTS</b>	58
<b>3.1. Consistent expression of DR5 but selective expression of DR4 in melanoma cells lines</b>	58
<b>3.2. High sensitivity to TRAIL-mediated apoptosis in DR4-positive melanoma cell lines</b>	61
<b>3.3. Cytotoxicity follows apoptotic cell death after TRAIL treatment</b>	61
<b>3.4. Strong activation of apoptosis cascades in DR4-positive melanoma cells</b>	63
<b>3.5. Significance of the mitochondrial pathway for TRAIL-induced apoptosis in melanoma cells</b>	65
<b>3.6. Prevalence of DR4 for TRAIL-induced apoptosis in cell lines expressing both receptors</b>	68
<b>3.7. Significant expression of DR4 and DR5 in primary melanomas</b>	71
<b>3.8. DR4-positive melanoma cells reveal high NF-<math>\kappa</math>B activation after TRAIL treatment</b>	73
<b>3.9. Parallel apoptosis induction and NF-<math>\kappa</math>B activation by TRAIL in DR4-positive melanoma cells</b>	76
<b>3.10. Increased NF-<math>\kappa</math>B activity by TRAIL is mediated through DR4</b>	76
<b>3.11. No changes in the levels of anti-apoptotic proteins after TRAIL treatment but decrease of DR4 in SK-Mel-13</b>	78
<b>3.12. Transient resistance of DR4 melanoma cells selected with TRAIL</b>	79
<b>3.13. Reduced activation of NF-<math>\kappa</math>B in TRAIL-resistant melanoma cells</b>	84

<b>3.14. TRAIL resistance of melanoma cells is related to downregulation of initiator caspases and DR4</b>	86
<b>3.15. TRAIL sensitivity can be restored by overexpression of initiator caspases and DR4 in selected cells and in resistant MeWo cells</b>	86
<b>4. DISCUSSION</b>	92
<b>4.1. High significance of DR4 expression in melanoma cells</b>	92
<b>4.1.1. Consistent expression of DR5 but limited of expressionDR4</b>	92
<b>4.1.2. High TRAIL-induced apoptosis in melanoma cells positive for DR4</b>	93
<b>4.1.3. Both TRAIL death receptors are expression in primary melanomas</b>	95
<b>4.1.4. Resistance to TRAIL-induced apoptosis caused by downregulation of initiator caspases and DR4</b>	96
<b>4.1.2. High TRAIL-induced NF-<math>\kappa</math>B activation in DR4 expressing melanoma cells</b>	98
<b>4.2.2. High NF-<math>\kappa</math>B is not the reason of upregulation of anti-apoptotic proteins</b>	98
<b>4.2.3. Resistance to TRAIL-induced apoptosis relates to downregulation of initiator caspases and DR4</b>	100
<b>5. SUMMARY</b>	103
<b>ZUSAMMENFASSUNG</b>	106
<b>6. REFERENCE LIST</b>	109
<b>7. LIST OF PUBLICATIONS</b>	123
<b>7.1. Original publications</b>	123
<b>7.2. Short publications/ Oral presentations / Posters</b>	123
<b>8. ABBREVIATIONS</b>	125
<b>CURRICULUM VITAE</b>	127
<b>Erklärung</b>	129
<b>Acknowledgement</b>	130